BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 29954071)

  • 1. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
    Rust A; Shah S; Hautbergue GM; Davletov B
    Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29954071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
    Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
    Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Rhodiola crenulata on growth and metabolism of NB-1691, an MYCN-amplified neuroblastoma cell line.
    Wong KE; Mora MC; Sultana N; Moriarty KP; Arenas RB; Yadava N; Schneider SS; Tirabassi MV
    Tumour Biol; 2018 Jun; 40(6):1010428318779515. PubMed ID: 29871587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
    Paffhausen T; Schwab M; Westermann F
    Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
    Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
    Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
    Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
    Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea.
    Narath R; Ambros IM; Kowalska A; Bozsaky E; Boukamp P; Ambros PF
    Genes Chromosomes Cancer; 2007 Feb; 46(2):130-42. PubMed ID: 17106870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
    Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
    Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
    Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
    J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.